The hepatic content of amyloid beta (Aβ) decreases drastically in human and rodent cirrhosis highlighting the importance of understanding the consequences of Aβ deficiency in the liver. This is especially relevant in view of recent advances in anti-Aβ therapies for Alzheimer’s disease (AD).
Here, it is shown that partial hepatic loss of Aβ in transgenic AD mice immunized with Aβ antibody 3D6 and its absence in amyloid precursor protein (APP) knockout mice (APP-KO), as well as in human liver spheroids with APP knockdown upregulates classical hallmarks of fibrosis, smooth muscle alpha-actin, and collagen type I. Conversely, increased systemic and intrahepatic levels of Aβ42 in transgenic AD mice and neprilysin inhibitor LBQ657-treated wild-type mice protect the liver against carbon tetrachloride (CCl4)-induced injury.
Adv. Sci. 2024 Mar 2
Metabolic syndrome is characterized by dysregulated glucose metabolism and is
We are pleased to announce that Innoprot has been recognised
Acetyl-l-carnitine (ALC) is synthesized in the brain, liver, and kidneys
Neural stem cell (NSC) proliferation and differentiation in the mammalian
Allergic conjunctivitis (AC) is the most common form of allergic
The hepatic content of amyloid beta (Aβ) decreases drastically in